Illumina Inc. Stock
Price
Target price
€163.16
€163.16
-2.030%
-3.38
-2.030%
€160.19
17.07.26 / Tradegate
WKN: 927079 / Symbol: ILMN / Name: Illumina / Stock / Healthcare Equipment & Supplies / Large Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
The full analysis of the stock Illumina Inc. is only available for our menbers.
Not a member yet? Sign up for free!
Not a member yet? Sign up for free!
Financial data and news for Illumina
sharewise wants to provide you with the best news and tools for Illumina, so we directly link to the best financial data sources.
Financials
News
GRAIL’s Galleri Test Cuts Stage 4 Cancer Diagnoses in Study Despite Missed Endpoint
Key Points
- Interested in GRAIL, Inc.? Here are five stocks we like better.
- GRAIL said its Galleri blood test showed it can shift cancer detection earlier and cut stage 4 diagnoses, with the
Prediction: Grail Stock Will Skyrocket to $100 in 1 Year
Grail (NASDAQ: GRAL), which was spun off from Illumina (NASDAQ: ILMN) in 2024, set a record high of $116.06 on Jan. 22. At the time, its Galleri blood test -- which aims to detect signals from
Is Grail Stock a Bad-News Buy After Its Recent Pullback?
Grail's (NASDAQ: GRAL) stock closed at a record high of $116.06 in January. That marked a 732% gain from its $13.95 opening price following its spin-off from Illumina (NASDAQ: ILMN) in June 2024
This Beaten-Down Growth Stock Could Soar 30%, According to Wall Street
Grail (NASDAQ: GRAL), a developer of multi-cancer early detection (MCED) tests, was spun off from Illumina (NASDAQ: ILMN) in June 2024. Its stock started trading at $13.95 per share, set a record